Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
TG Therapeutics began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate IV ublituximab given on days 1 and 15 and week 24 in about 40 patients. The company has exclusive, worldwide r...